For example, PRC2-mediated silencing of MHC-I antigen processing and presentation genes can be alleviated through the pharmacological inhibition of polycomb repressive complex 2 (PRC2) components, including Menin and EZH2 inhibitors, which have been shown to restore MHC-I expression in SCLC cell lines and enhance durable responses to ICIs [4, 9, 10]. This evidence concerns the gene MEN1 and small cell lung carcinoma.